Trial Profile

A Prospective Observational Registry of Patients Treated With LUPKYNIS 174; (Voclosporin) in the US

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 15 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Voclosporin (Primary)
Indications Lupus nephritis
Focus Therapeutic Use
Acronyms Enlight-LN
Sponsors Aurinia Pharmaceuticals

Most Recent Events

11 Oct 2024 According to Aurinia Pharmaceuticals Inc. media release, company will present new data highlighting the important role that LUPKYNIS in Treating Lupus Nephritis will be presented at the American Society of Nephrology (ASN) Kidney Week 2024 taking place in San Diego, CA October 23-27.
22 May 2024 Planned End Date changed from 15 Feb 2027 to 1 Jun 2030.
14 May 2024 Results presented in the Aurinia Pharmaceuticals Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com